Seizert Capital Partners LLC trimmed its position in Celgene Co. (NASDAQ:CELG) by 20.4% during the 1st quarter, according to its most recent Form 13F filing with the SEC. The fund owned 282,018 shares of the biopharmaceutical company’s stock after selling 72,484 shares during the period. Seizert Capital Partners LLC’s holdings in Celgene were worth $26,606,000 as of its most recent SEC filing.
A number of other large investors have also recently made changes to their positions in the business. Altium Wealth Management LLC lifted its position in shares of Celgene by 1.3% during the 1st quarter. Altium Wealth Management LLC now owns 8,980 shares of the biopharmaceutical company’s stock valued at $847,000 after buying an additional 115 shares in the last quarter. Global Retirement Partners LLC raised its stake in Celgene by 10.0% during the 1st quarter. Global Retirement Partners LLC now owns 1,269 shares of the biopharmaceutical company’s stock valued at $120,000 after purchasing an additional 115 shares during the period. Janney Capital Management LLC raised its stake in Celgene by 2.9% during the 4th quarter. Janney Capital Management LLC now owns 4,219 shares of the biopharmaceutical company’s stock valued at $270,000 after purchasing an additional 120 shares during the period. Community Bank N.A. raised its stake in Celgene by 3.2% during the 1st quarter. Community Bank N.A. now owns 3,922 shares of the biopharmaceutical company’s stock valued at $370,000 after purchasing an additional 120 shares during the period. Finally, Iberiabank Corp raised its stake in Celgene by 1.0% during the 1st quarter. Iberiabank Corp now owns 12,019 shares of the biopharmaceutical company’s stock valued at $1,134,000 after purchasing an additional 121 shares during the period. 70.78% of the stock is currently owned by institutional investors and hedge funds.
NASDAQ:CELG opened at $95.24 on Friday. The company has a debt-to-equity ratio of 2.42, a quick ratio of 2.66 and a current ratio of 2.78. Celgene Co. has a 1 year low of $58.59 and a 1 year high of $97.07. The company has a market capitalization of $67.17 billion, a price-to-earnings ratio of 12.52, a PEG ratio of 0.44 and a beta of 1.68.
Celgene (NASDAQ:CELG) last released its quarterly earnings data on Thursday, April 25th. The biopharmaceutical company reported $2.55 earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of $2.45 by $0.10. Celgene had a return on equity of 106.69% and a net margin of 30.10%. The business had revenue of $4.03 billion for the quarter, compared to the consensus estimate of $4.01 billion. During the same quarter in the previous year, the company posted $2.05 EPS. The company’s revenue was up 13.8% compared to the same quarter last year. On average, equities analysts expect that Celgene Co. will post 9.85 earnings per share for the current fiscal year.
Several analysts recently issued reports on the company. BidaskClub raised Celgene from a “buy” rating to a “strong-buy” rating in a research note on Friday. Mizuho reissued a “buy” rating and set a $103.00 target price on shares of Celgene in a research note on Thursday, May 16th. ValuEngine raised Celgene from a “sell” rating to a “hold” rating in a research note on Saturday, May 4th. Barclays downgraded Celgene from an “overweight” rating to an “equal weight” rating and set a $102.00 target price on the stock. in a research note on Friday, May 3rd. Finally, Cantor Fitzgerald downgraded Celgene from an “overweight” rating to a “neutral” rating and set a $94.00 target price on the stock. in a research note on Friday, April 5th. Eighteen equities research analysts have rated the stock with a hold rating, five have assigned a buy rating and one has issued a strong buy rating to the company’s stock. The company presently has an average rating of “Hold” and an average target price of $95.56.
ILLEGAL ACTIVITY WARNING: This piece of content was posted by Stock Observer and is owned by of Stock Observer. If you are reading this piece of content on another site, it was illegally stolen and republished in violation of United States & international copyright and trademark laws. The legal version of this piece of content can be read at https://www.thestockobserver.com/2019/05/25/seizert-capital-partners-llc-reduces-holdings-in-celgene-co-celg.html.
Celgene Company Profile
Celgene Corporation, a biopharmaceutical company, discovers, develops, and commercializes therapies for the treatment of cancer and inflammatory diseases worldwide. It offers REVLIMID, an oral immunomodulatory drug for multiple myeloma (MM), myelodysplastic syndromes (MDS), and mantle cell lymphoma; POMALYST/IMNOVID to treat multiple myeloma; OTEZLA, a small-molecule inhibitor of phosphodiesterase 4 for psoriatic arthritis and psoriasis; and ABRAXANE to treat breast, non-small cell lung, pancreatic, and gastric cancers.
Want to see what other hedge funds are holding CELG? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Celgene Co. (NASDAQ:CELG).
Receive News & Ratings for Celgene Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Celgene and related companies with MarketBeat.com's FREE daily email newsletter.